Ipamorelin vs CJC-1295 DAC
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: IPAM, NNC 26-0161
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk and derived from GHRP-1. It is researched mainly for stimulating the body's own growth hormone (GH) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. It is not an approved drug anywhere: it reached Phase II trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical.
Also: Modified GRF 1-29 DAC, Drug Affinity Complex CJC
CJC-1295 DAC is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH), built from a modified GRF(1-29) sequence with four amino acid swaps plus a Drug Affinity Complex (DAC) that lets it latch onto your own albumin after injection. That albumin trick stretches its half-life from minutes to roughly 6 to 8 days, so a single shot keeps nudging growth hormone and IGF-1 up for over a week. It is not FDA approved for any use; it was an investigational drug whose company development was halted, and today it circulates only as a research-grade or gray-market peptide.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
Detailed Comparison
| Attribute | Ipamorelin | CJC-1295 DAC |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Ipamorelin is an agonist of the ghrelin / growth hormone secretagogue receptor (GHS-R1a) on the somatotroph cells of the anterior pituitary. Binding this receptor triggers intracellular signaling (Gq/phospholipase C, IP3 and calcium release) that makes the pituitary release stored GH in pulses, mimicking natural ghrelin. Its defining feature, established in the original 1998 characterization, is selectivity: at GH-releasing doses it does not meaningfully raise ACTH, cortisol, prolactin, FSH, LH or TSH, making it cleaner than older peptides like GHRP-2 and GHRP-6. Because it works on the pituitary's own GH reserves, the effect depends on a functioning pituitary and natural feedback loops stay in place. | GHRH is the natural signal your hypothalamus sends to the pituitary to release growth hormone in pulses. CJC-1295 binds and activates the same GHRH receptor on the pituitary, prompting it to make and release more of its own growth hormone, which then raises IGF-1 from the liver. The four amino acid substitutions make it resist breakdown by the enzyme DPP-IV, and the DAC linker covalently bonds it to circulating albumin so it is not cleared quickly. Because it amplifies the body's own pulsatile signaling rather than injecting growth hormone directly, the effect is a sustained elevation rather than a single spike. |
| Common Dosing | 200-300 mcg 2-3x daily 2-3x daily | Limited community data available See research protocols |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Duration | 8-12 weeks typical | 8-12 weeks typical |
| Best Time to Take | Before bed or morning (fasted) | Before bed or morning (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The foundational work is Raun et al. (1998) in the European Journal of Endocrinology, which characterized ipamorelin in rats, pigs and isolated pituitary cells and named it the first selective growth hormone secretagogue, releasing GH without raising ACTH or cortisol even at doses far above the GH-releasing dose. Most rigorous data is preclinical. In humans, the compound was advanced into Phase II trials for postoperative ileus but was discontinued for insufficient efficacy. There are no large peer-reviewed human randomized controlled trials supporting the popular anti-aging, fat-loss, muscle-gain or recovery claims; those uses are extrapolations from the mechanism, not proven outcomes. Honestly stated: the receptor mechanism and GH-release effect are well documented, but human efficacy and long-term safety for wellness use are not established. | The core human evidence is a single early-phase study, Teichman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 2006, in healthy adults. A single subcutaneous dose raised GH roughly 2 to 10 fold and IGF-1 about 1.5 to 3 fold, with GH staying up for 6 days or more and IGF-1 elevated for 9 to 11 days, and repeated dosing kept IGF-1 above baseline for up to 28 days. The estimated half-life was about 5.8 to 8.1 days and no serious adverse reactions were reported in that short trial. Beyond that, the data is mostly animal work, such as a study showing once-daily CJC-1295 normalized growth in GHRH knockout mice. Importantly, clinical development by the original sponsor (ConjuChem) was stopped, and a related long-acting analog program saw a Phase II lipodystrophy study halted after a participant death, although the attending physician attributed that death to pre-existing coronary disease rather than the drug. So the honest read is: short-term pharmacology in humans is documented, but there are no long-term safety or efficacy trials, no approval, and real questions about chronically elevating IGF-1. |
Frequently Asked Questions: Ipamorelin vs CJC-1295 DAC
What is the difference between Ipamorelin and CJC-1295 DAC?
Ipamorelin is a growth hormone peptide that ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by novo nordisk and derived from ghrp-1. it is researched mainly for stimulating the body's own growth hormone (gh) release, and was studied in humans primarily for postoperative ileus and gut motility rather than anti-aging. it is not an approved drug anywhere: it reached phase ii trials, was discontinued for insufficient efficacy, and is now sold only as a research chemical. CJC-1295 DAC is a growth hormone peptide that cjc-1295 dac is a synthetic, long-acting analog of growth hormone-releasing hormone (ghrh), built from a modified grf(1-29) sequence with four amino acid swaps plus a drug affinity complex (dac) that lets it latch onto your own albumin after injection. that albumin trick stretches its half-life from minutes to roughly 6 to 8 days, so a single shot keeps nudging growth hormone and igf-1 up for over a week. it is not fda approved for any use; it was an investigational drug whose company development was halted, and today it circulates only as a research-grade or gray-market peptide. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Ipamorelin or CJC-1295 DAC?
Neither is universally "better" - the choice depends on your specific goals. Ipamorelin is typically used for growth hormone purposes, while CJC-1295 DAC is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Ipamorelin and CJC-1295 DAC be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Ipamorelin and CJC-1295 DAC together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.